ALK and non-small cell lung carcinoma: A retrospective analysis of two randomized clinical trials (PROFILE 1005 and 1007) examined the intracranial response to crizotinib in patients with ALK-positive NSCLC BM, and found intracranial disease control rates of 56-62% [28].